Drug therapy

Drug therapy of vascular anomalies was long regarded as supportive or palliative therapy only. In addition to compression therapy, invasive and surgical procedures were mainly used at that time.

Coagulation anomalies play a major role in patients with vascular anomalies and, under certain circumstances, require appropriate drug therapy.

Blood coagulation disorders can occur in patients, especially those with large-volume venous malformations (VM) because of persistent localized coagulation phenomena in the sense of LIC; these must be specifically treated. A large part of the pain in patients with venous malformations is also associated with coagulation phenomena that lead to localized thrombophlebitis within the lesion.

Patients with the rare kaposiform hemangioendothelioma may develop a Kasabach-Merritt phenomenon, for which drug therapy is also specific.

In the treatment of infantile hemangioma, drug therapy with beta blockers is now actually the drug therapy of choice, which is a real breakthrough.